Navigation Links
Resverlogix Issues a Management Statement
Date:10/7/2008

TSX Exchange Symbol: RVX

CALGARY, Oct. 7 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that in light of the recent significant market drop of Resverlogix shares management feels it is prudent to restate that the company fundamentals remain the same if not stronger in regards to the Company's science and business developments. There is no reason for the price drop other than the current global conditions. Management will present an update as to the current business development discussions at the Annual General Meeting on October 28th, at the Telus Convention Centre in Calgary Alberta at 2:00pm

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial ... microbiome impact grant award has been made to Dr. Renato Polimanti of Yale ... drinking on the oral microbiome. Grant proposals have been vetted by the company’s ...
(Date:12/2/2016)... Dec. 2, 2016 More than $4.3 million was ... Medals dinner ( DHMD ). The gala was held at the ... York City and honored Alan Alda ... to health and medicine and the public understanding of science. ... 2006, the event has raised $40 million for the Laboratory,s ...
(Date:12/2/2016)... , Dec 2, 2016 Research and ... "Nanobiotechnology Applications, Markets and Companies" to their offering. ... , , ... by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will ... formulations for optimal delivery to diagnostic applications in clinical trials. ...
(Date:12/2/2016)... , ... December 01, 2016 , ... ... Science Symposium (CSS) and the popularity of US Single Day Events (SDE) to ... in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life ...
Breaking Biology Technology:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):